Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Shares Outstanding (2016 - 2025)

Neuronetics (STIM) has disclosed Shares Outstanding for 10 consecutive years, with $68.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 125.76% to $68.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $68.4 million, a 125.76% increase, with the full-year FY2024 number at $55.7 million, up 91.39% from a year prior.
  • Shares Outstanding was $68.4 million for Q3 2025 at Neuronetics, up from $66.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $68.4 million in Q3 2025 to a low of $25.8 million in Q1 2021.
  • A 5-year average of $35.5 million and a median of $28.8 million in 2023 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: increased 2.63% in 2022, then surged 125.76% in 2025.
  • Neuronetics' Shares Outstanding stood at $26.4 million in 2021, then increased by 3.31% to $27.3 million in 2022, then grew by 6.69% to $29.1 million in 2023, then surged by 91.39% to $55.7 million in 2024, then increased by 22.93% to $68.4 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's Shares Outstanding are $68.4 million (Q3 2025), $66.1 million (Q2 2025), and $65.8 million (Q1 2025).